Cargando…

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review

Low-grade gliomas (LGG) encompass a heterogeneous group of tumors that are clinically, histologically and molecularly diverse. Treatment decisions for patients with LGG are directed toward improving upon the natural history while limiting treatment-associated toxiceffects. Recent evidence has docume...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hafazalla, Karim, Sahgal, Arjun, Jaja, Blessing, Perry, James R., Das, Sunit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154749/ https://www.ncbi.nlm.nih.gov/pubmed/30263090 http://dx.doi.org/10.18632/oncotarget.25890

Ejemplares similares

Procarbazine, CCNU, and Vincristine Chemotherapy in Gliomatosis Cerebri
por: Lee, Hyun Gon, et al.
Publicado: (2014)

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
por: Kim, Se-Hyuk, et al.
Publicado: (2018)

Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review
por: Irfan, Nabia, et al.
Publicado: (2020)

Clinical feasibility of modified procarbazine and lomustine chemotherapy without vincristine as a salvage treatment for recurrent adult glioma
por: Ahn, Stephen, et al.
Publicado: (2022)

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
por: McDuff, Susan G. R., et al.
Publicado: (2019)

Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas
por: Kim, Young-Joo, et al.
Publicado: (2015)

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Kaka, Nagham, et al.
Publicado: (2019)

Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
por: Das, Sunit, et al.
Publicado: (2020)

One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre
por: Keogh, Rachel J., et al.
Publicado: (2021)

Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma
por: Sung, Kang Hyun, et al.
Publicado: (2011)

A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis
por: Cai, Yang, et al.
Publicado: (2020)

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
por: Lassman, Andrew B., et al.
Publicado: (2022)

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
por: Kuan, Jew Win, et al.
Publicado: (2022)

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
por: Yung, W K A, et al.
Publicado: (2000)

AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes
por: Zhang, Shuai, et al.
Publicado: (2021)

Chemopotentiation of CCNU metabolites by misonidazole.
por: Mulcahy, R. T.
Publicado: (1985)

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
por: Baer, J. C., et al.
Publicado: (1993)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas
por: Newlands, E S, et al.
Publicado: (2003)

Protection of rat spermatogenic epithelium from damage induced by procarbazine chemotherapy.
por: Glode, L. M., et al.
Publicado: (1990)

Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade
por: Hata, Nobuhiro, et al.
Publicado: (2016)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Editorial: Contemporary Management of Intracranial Metastatic Disease
por: Das, Sunit, et al.
Publicado: (2019)

Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.
por: Durand, R. E., et al.
Publicado: (1987)

In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
por: Siemann, D. W.
Publicado: (1981)

Cisplatin and CCNU synergism in spheroid cell subpopulations.
por: Durand, R. E.
Publicado: (1990)

ML-14 LOW INVASIVE APPROACH FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATMENT INVOLVING RITUXIMAB–METHOTREXATE + PROCARBAZINE + VINCRISTINE AND TRIPLE INTRATHECAL INJECTION
por: Ogawa, Takahiro, et al.
Publicado: (2019)

RE-IRRADIATION FOR RECURRENT HIGH-GRADE GLIOMA: AN ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL AND PREDICTORS OF RADIATION NECROSIS
por: Moore-Palhares, Daniel, et al.
Publicado: (2023)

Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
por: Osman, Mohammed A
Publicado: (2014)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Successful Treatment of Intracranial Methotrexate-associated Lymphoproliferative Disorder without Epstein-Barr Virus Infection Using Rituximab, Methotrexate, Procarbazine, and Vincristine: A Case Report
por: MIZUSHIMA, Makoto, et al.
Publicado: (2022)

Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
por: Hirst, D. G., et al.
Publicado: (1982)

Response of two mouse tumours to hyperthermia with CCNU or melphalan.
por: Joiner, M. C., et al.
Publicado: (1982)

Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.
por: Zimber, A., et al.
Publicado: (1988)

Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
por: Li, Ze-Yang, et al.
Publicado: (2021)

Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors
por: Armand, Jean-Pierre, et al.
Publicado: (2007)

Initial PCV Chemotherapy Followed by Radiotherapy Is Associated With a Prolonged Response But Late Neurotoxicity in 20 Diffuse Low-Grade Glioma Patients
por: Blonski, Marie, et al.
Publicado: (2022)

Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy
por: Sengupta, Sadhak, et al.
Publicado: (2012)

Temozolomide in paediatric high-grade glioma: a key for combination therapy?
por: Verschuur, A C, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_p462t0o2g41et85jljng8g1sk1